Skip to main content
Figure 5 | Journal of Translational Medicine

Figure 5

From: CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab

Figure 5

Long-term treatment of HNSCC cells with cisplatin or cetuximab selects resistant subclones. Cell lines were treated for 6-9 months with increasing doses of (A) cisplatin (FaDuCDDP-S, UD-SCC-4CDDP-S) or (B) cetuximab (UT-SCC-9CET-S, UM-SCC-22BCET-S). Doses were elevated if the cells showed a stable growth. The resulting resistant cells (CDDP-/CET-R) as well as their sensitive parental counterparts (CDDP-/CET-S) were used forfurther experiments.

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us